biochimica clinica

en_US English
en_US English it_IT Italian

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica, 48 (3) pag 224-30

Pubblicato on-line:

March 1, 2024

DOI:

10.19186/BC_2024.010

Scarica in PDF:
Autenticazione richiesta

Monitoring dexamethasone suppression test by simultaneous LC-MS/MS measurement of cortisol, cortisone and dexamethasone in serum samples

AUTORI

Federico Ponzetto1, Laura Leoni2, Mirko Parasiliti-Caprino1, Antonello Nonnato3, Fabio Settanni3, Giulio Mengozzi2,3
1Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Torino , Italy
2Clinical Biochemistry Laboratory, Department of Medical Sciences, University of Torino, Italy
3Clinical Biochemistry Laboratory, City of Health and Science University Hospital, Torino, Italy

ABSTRACT

Background: the simultaneous monitoring of dexamethasone and cortisol serum concentrations by LC-MS/MS has recently proven to effectively increase the diagnostic performance of overnight dexamethasone suppression in comparison to cortisol immunometric measurement performed in the majority of clinical biochemistry laboratories.
Methods: an in-house LC-MS/MS method for the quantification of cortisol, cortisone and dexamethasone in serum/plasma matrix was employed for the analysis of 297 serum samples collected from patients with suspected hypercortisolism subjected to dexamethasone suppression tests at three different dosages. Cortisol concentrations obtained by
LC-MS/MS analysis were also compared with the one resulted from routine chemiluminescent immunoassay (CLIA) measurements.
Results: dexamethasone concentrations were significantly different in patients performing the low-dose dexamethasone suppression test (LDDST) and dexamethasone suppression test (DST) and higher than the proposed cut-off for accepting dexamethasone suppression test results for all tested patients. LC-MS/MS showed a negative bias of 6.8% when compared to CLIA method, with relevant differences at low concentrations. Cortisol and cortisone showed similar concentration patterns in patient categorized as positive or negative to LLDST and DST by cortisol immunometric measurement.
Conclusions: the present study proved the overall performance of previously developed LC-MS/MS method for the measurement of cortisol, cortisone and dexamethasone in real clinical serum samples, guaranteeing a single and versatile analytical tool to be implemented in clinical biochemistry laboratory’s routine. The obtained results showed that the administered dexamethasone dosage was sufficient to reach test acceptance threshold in all monitored patients; the correlation between cortisol and cortisone serum concentrations could open the way to the future addition of cortisone measurement to the monitoring dexamethasone suppression test results.

BIBLIOGRAFIA

  1. Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 1993;45:S3-7.
  2. De Keyser J, Zwanikken C, Zorgdrager A, Oenema D, Boon M. Treatment of acute relapses in multiple sclerosis at home dexamethasone: a pilot study. J Clin Neurosci 1999;6:382-4.
  3. Parasiliti-Caprino M, Bioletto F, Frigerio T, D’Angelo V, Ceccato F, Ferraù F, et al. A New clinical model to estimate the pre-test probability of cushing’s syndrome: the cushing score. Front Endocrinol 2021;12:747549.
  4. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:1526-40.
  5. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 2021;9:847-75.
  6. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol 2016;175:G1-34.
  7. Chiodini I, Ramos-Rivera A, Marcus AO, Yau H. Adrenal hypercortisolism: a closer look at screening, diagnosis, and important considerations of different testing modalities. J Endocr Soc 2019;3:1097-109.
  8. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-602.
  9. Ceccato F, Marcelli G, Martino M, Concettoni C, Brugia M, Trementino L, et al. The diagnostic accuracy of increased late night salivary cortisol for Cushing’s syndrome: a real-life prospective study. J Endocrinol Invest 2019;42:327-35.
  10. Ponzetto F, Settanni F, Parasiliti-Caprino M, Rumbolo F, Nonnato A, Ricciardo M, et al. Reference ranges of late-night salivary cortisol and cortisone measured by LC–MS/MS and accuracy for the diagnosis of cushing’s syndrome. J Endocrinol Invest 2020;43:1797-806.
  11. Lavagnino L, Amiant F, Parasiliti Caprino M, Maccario M, Arvat E, Ghigo E, et al. Urinary cortisol and psychopathology in obese binge eating subjects. Appetite 2014;83:112-6.
  12. Elias PCL, Martinez EZ, Barone BFC, Mermejo LM, Castro M, Moreira AC. Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 2014;99:2045-51.
  13. Meikle AW. Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol 1982;16:401-8.
  14. Morris H, Varr V, Gilliland J, Hooper M. Dexamethasone concentrations and the dexamethasone suppression test in psychiatric disorders. Br J Psychiatry 1986;148:66-9.
  15. O’Sullivan BT, Cutler DJ, Hunt GE, Walters C, Johnson GF, Caterson ID. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry 1997;41:574-84.
  16. Guthrie S. The impact of dexamethasone pharmacokinetics on the DST: a review. Psychopharmacol Bull 1991;27:565-76.
  17. Vilar L, Freitas MDC, Faria M, Montenegro R, Casulari LA, Naves L, et al. Pitfalls in the diagnosis of Cushing’s syndrome. Arq Bras Endocrinol Metab 2007;51:1207-16.
  18. Ueland GA, Methlie P, Kellmann R, Bjørgaas MA, Svold BO, Thorstensen K, et al. Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. Eur J Endocrinol 2017;176:705-13.
  19. de Graaf AJ, Mulder AL, Krabbe JG. Retrospective analysis of repeated dexamethasone suppression tests – the add-ed value of measuring dexamethasone. Ann Clin Biochem 2019; 56:707-10.
  20. Ponzetto F, Parasiliti-Caprino M, Settanni F, Nonnato A, Mengozzi G, Ghigo E, et al. Simultaneous Measurement of Cortisol, Cortisone, Dexamethasone and Additional Exogenous Corticosteroids by Rapid and Sensitive LC-MS/MS Analysis. Molecules 2022;28:248.
  21. Passing H, Bablok L. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear egression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983;21:709-20.
  22. Altman DG, Bland JM, Measurements in medicine: the analysis of method comparison studies. Statistician 1983;32:307-17.
  23. Bland JM, Altman DG, Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
  24. Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb) 2015;25:141-151.